Clinical Trial

A Study on Multimodal Prognostic Scoring of Advanced PDAC.

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to construct unimodal and multimodal prediction models for overall survival (OS), progression free survival (PFS), and treatment response (complete response+partial response) of advanced first-line chemotherapy based on the imaging, pathological, and genomic characteristics of patients, and evaluate their predictive efficacy.
Trial Details
NCT Number NCT07373691
Lead Sponsor RenJi Hospital
Collaborators: Shanghai Zhongshan Hospital, Sir Run Run Shaw Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Third Affiliated Hospital, Sun Yat-Sen University
Conditions Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 100 participants
Start Date 2025-03-02
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28